Palatin Technologies, Inc. (PTN)
| Market Cap | 17.79M |
| Revenue (ttm) | 2.38M |
| Net Income (ttm) | -32.35M |
| Shares Out | 19.55M |
| EPS (ttm) | -1.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 172,260 |
| Open | 0.930 |
| Previous Close | 0.930 |
| Day's Range | 0.900 - 0.950 |
| 52-Week Range | 0.680 - 5.650 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+1,768.13%) |
| Earnings Date | Nov 14, 2024 |
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]
Financial Performance
In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PTN stock is "Strong Buy" and the 12-month stock price forecast is $17.0.
News
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
Palatin Technologies, Inc. (NYSE:PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secret...
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide pl...
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
CRANBURY, N.J. , Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before ...
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Oral PL7737 significantly decreased food intake and body weight Oral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatments Multiple clinic...
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Topline results expected in 1Q calendar year 2025 Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight Data will inform and support the Company's obesity p...
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Data presented from clinical and preclinical studies Melanocortin agonism reduces stress signaling and resolves inflammation Potential to treat inflammatory diseases without immunosuppression CRANBURY...
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
High selectivity for MC4R significantly reduces potential for skin pigmentation MC4R is a well-validated target for treating obesity Clinical studies with highly selective MC4R agonists targeted to co...
Palatin Receives Notice of Non-Compliance from NYSE American
CRANBURY, N.J. , Oct. 7, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti...
Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript
Palatin Technologies, Inc. (NYSE:PTN) Q4 2024 Earnings Conference Call October 1, 2024 11:00 AM ET Company Participants Carl Spana - Chief Executive Officer and President Stephen Wills - Chief Financ...
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year 2024 Patient Enrollment Expected to be Comple...
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J. , Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal yea...
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Targeting Enrollment Start in 4Q Calendar Year 2024 Topline Results Anticipated ...
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
FDA & Palatin agree on clear regulatory path for PL9643 NDA submission in DED FDA confirms acceptability of protocols and endpoints for remaining MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Trials in...
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Complete enrollment currently expected in 3Q 2024 Topline results expected in 1Q calendar year 2025 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J. , Aug. 22, 2024...
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Publishe...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additiona...
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the o...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's met...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ac...
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P
Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral ...